title: CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
abstract: The Joint United Nations Program on HIV-1/AIDS (UNAIDS) announced its goal to stop HIV-1 transmission by antiviral (HAART) treatment of patients since at the end of 2003 the number of people living with HIV-1 was 38 million, 25 million in the sub-Saharan region of Africa. The present review deals with a new approach to simultaneously treat HIV-1/AIDS patients in HIV-1 endemic regions with CpG oligodeoxynucleotides (ODNs) and people at high risk of infection with a vaccine containing CpG ODNs combined with synthetic HIV-1 peptides by intranasal and intradermal applications. During HIV-1 infection a gradual increase in the levels of IL-4 and IgE in the patients' serum, was reported. It was suggested that such an increase of the cytokine IL-4 and the IgE immunoglobulin are interconnected and may serve as indicators for the coming stage of AIDS. It was also suggested that the IL-4 and IgE increase in the serum of HIV-1 infected people resemble the increase of IL-4 and IgE levels in allergic patients that were exposed to endogenous or environmental allergens [Becker, Virus Genes 28, 5--18, 2004]. Indeed, it was reported that the HIV-1 virions' shed gp120 molecules, which contain a superantigen (superallergen) domain that enables the viral glycoprotein to bind the V(H)3 domain of IgE molecules that are bound to FcepsilonRI+ hematopoietic cells [basophils, mast cells, dendritic cells (DCs) and plasmacytoid DCs (pDCs)]. Such interaction was reported to induce the hematopoietic cells to release large amounts of Th2 cytokines IL-4, IL-5, IL-10 and IL-13. These findings led to the hypothesis [Op. cit.] that the cure of HIV-1/AIDS patients requires the induction of endogenous synthesis of type I interferons (INF alpha and beta) with a bacterial CpG rich DNA that will induce the patients' pDCs to release large amounts of type I IFNs. Under these conditions HIV-1 replication in polarized to Th2 cells is inhibited. Type I IFNs reactivate the patients' inhibited Th1 cells to synthesize IL-2 and IL-12 cytokines that activate the maturation of CTL precursors. The unmethylated bacterial DNA activates B synthesis to switch to IgG and IgA synthesis. The novel drug CpG ODNs is being tested for the prevention and the treatment of allergic humans and in the experimental system of allergic mice. It was also reported that treatment of mice with CpG ODN prior to or after retrovirus infections protected and cured, respectively, the retrovirus infection. It was also reported that CpG ODNs treatments of mice exposed to allergen protected them against the development of the allergic response. Phase I treatment of healthy people with CpG ODNs provided information on the safety of these compounds. The CpG ODNs A and B bind to Toll like receptors that are present in pDCs and B cells, respectively, CpG ODN - A is the ligand for TLR9+ pDCs and induce the release of large amounts of IFN-alpha, beta. CpG ODN-B is the ligand for TLR9+ in B cells and induce the synthesis of IgG and IgA. CpG ODN-C contains motifs from CpG ODNs A and B and is more active. The present review is based on findings from studies that reported that CpG ODNs treatment of retrovirus infected mice, monkeys and allergic mice prevented the virus and allergens caused diseases, respectively. Based on these studies, a hypothesis is presented that treatment of HIV-1 infected and AIDS patients with CpG ODN-A and B or CpG ODN-C have the potential to inhibit IL-4 synthesis and release from FcrepsilonRI+ hematopoietic cells by inducing TLR9+ pDCs to release large amounts of type I IFNs. TLR9+ B cells are induced by CpG ODN-B to switch from IgE to IgG, IgA synthesis. In addition, type I IFNs (alpha, beta) have the capacity to inhibit HIV-1 replication in polarized Th2 cells. Type I IFNs reactivate the patients' Th1 cells to synthesize IL-2 and IL-12 cytokines, activators of the precursor cytotoxic T cells (CTLs), leading to the reactivation of the inhibited adaptive immune response. Antiviral CTLs have the ability to clear the virus infection. The present novel approach to the treatment and of HIV-1/AIDS patients with CpG ODNs may prevent HIV-1 transmission and the AIDS pandemic if controlled studies on the treatments with CpG ODNs of HIV-1 infected people will be done by international and private agencies and companies to define the effective treatment regime and the efficacy of the treatments to HIV-1 infected people at different times post-infection. It is also hypothesized that in order to stop HIV-1 transmission in HIV-1 endemic regions the people at high risk of HIV-1 infection should be treated at the same time as HIV-1 infected people with a vaccine containing synthetic CpG-ODNs combined with synthetic HIV-1 peptides, compatible with the major HLA haplotypes of the regional population. The vaccine may be self-applied by people at high risk of infection by the intra-nasal route and by intra-dermal application as a "peplotion vaccine". The stimulation of the antiviral CTL response by HIV-1 infected people and the active antiviral immune response in the vaccinated population may lead to a decline in HIV-1 transmission and may be a model for control of the HIV-1/AIDS pandemic.
authors.affiliation: Department of Molecular Virology, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. becker@md.huji.ac.il
authors.forename: Yechiel
authors.initials: Y
authors.lastname: Becker
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D016207:Cytokines / Q000097:blood; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control / Q000635:transmission; D015497:HIV-1; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D007073:Immunoglobulin E / Q000097:blood; D008562:Membrane Glycoproteins / Q000276:immunology; D051379:Mice; D018448:Models, Immunological; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use*; D011956:Receptors, Cell Surface / Q000276:immunology; D012307:Risk Factors; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051217:Toll-Like Receptor 9; D051193:Toll-Like Receptors
chemical_list: D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D016207:Cytokines; D008562:Membrane Glycoproteins; D009838:Oligodeoxyribonucleotides; D011956:Receptors, Cell Surface; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9; D051193:Toll-Like Receptors; D007073:Immunoglobulin E
references.citation: Clin Exp Immunol. 2003 Aug;133(2):227-32
references.pmid: 12869028
references.citation: Eur J Immunol. 2001 Jul;31(7):2154-63
references.pmid: 11449369
references.citation: Vaccine. 2003 Jun 2;21(19-20):2461-7
references.pmid: 12744879
references.citation: Eur J Immunol. 2001 Oct;31(10):3026-37
references.pmid: 11592079
references.citation: Clin Immunol. 2003 Oct;109(1):64-71
references.pmid: 14585277
references.citation: Curr Med Chem. 2003 Aug;10(15):1423-39
references.pmid: 12871139
references.citation: Virus Genes. 2004 Jan;28(1):5-18
references.pmid: 14739648
references.citation: Nat Med. 2003 Jul;9(7):874-80
references.pmid: 12835708
references.citation: Curr Opin Microbiol. 2003 Oct;6(5):472-7
references.pmid: 14572539
references.citation: Semin Immunol. 2004 Feb;16(1):17-22
references.pmid: 14751759
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14303-8
references.pmid: 14610275
references.citation: AIDS. 2004 Apr 30;18(7):1003-8
references.pmid: 15096802
references.citation: Semin Immunol. 2004 Feb;16(1):27-34
references.pmid: 14751761
references.citation: J Leukoc Biol. 2001 Jul;70(1):103-12
references.pmid: 11435492
references.citation: Virus Genes. 2004 Aug;29(1):147-65
references.pmid: 15215692
references.citation: Curr Opin Immunol. 2002 Oct;14(5):644-51
references.pmid: 12183167
references.citation: J Immunol. 2004 Jul 15;173(2):1219-23
references.pmid: 15240713
references.citation: Science. 2003 Jun 6;300(5625):1527-8
references.pmid: 12791978
references.citation: J Leukoc Biol. 2003 Jun;73(6):781-92
references.pmid: 12773511
references.citation: Nat Rev Immunol. 2004 Apr;4(4):249-58
references.pmid: 15057783
references.citation: Immunol Today. 1996 Mar;17(3):138-46
references.pmid: 8820272
references.citation: J Leukoc Biol. 2000 Oct;68(4):455-63
references.pmid: 11037965
references.citation: J Allergy Clin Immunol. 2002 Nov;110(5):706-12
references.pmid: 12417878
references.citation: Hum Immunol. 2002 Dec;63(12):1111-9
references.pmid: 12480254
references.citation: Virus Genes. 1995;10(3):227-37
references.pmid: 8560784
references.citation: J Immunol. 1986 Apr 1;136(7):2348-57
references.pmid: 2419430
references.citation: Vet Immunol Immunopathol. 2003 Jan 10;91(1):1-12
references.pmid: 12507844
references.citation: Clin Immunol Immunopathol. 1983 Jun;27(3):315-25
references.pmid: 6223758
references.citation: J Immunol. 2003 May 1;170(9):4717-23
references.pmid: 12707351
references.citation: Vaccine. 2002 Jul 26;20(23-24):2857-65
references.pmid: 12126895
references.citation: J Immunol. 2003 Oct 15;171(8):4320-8
references.pmid: 14530357
references.citation: Science. 1999 Jun 11;284(5421):1835-7
references.pmid: 10364556
references.citation: Adv Exp Med Biol. 1996;397:97-104
references.pmid: 8718588
references.citation: Altern Med Rev. 2003 Aug;8(3):223-46
references.pmid: 12946237
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8852-5
references.pmid: 1528902
references.citation: J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):124-34
references.pmid: 10887315
references.citation: J Immunol. 2000 Nov 15;165(10):5472-9
references.pmid: 11067899
references.citation: Drugs R D. 2003;4(4):249-53
references.pmid: 12848591
references.citation: J Infect Dis. 2002 Oct 15;186(8):1098-105
references.pmid: 12355360
references.citation: Immunol Today. 1993 Mar;14(3):107-11
references.pmid: 8096699
references.citation: J Immunol. 1998 Mar 15;160(6):2555-9
references.pmid: 9510150
references.citation: J Immunol. 2003 Oct 15;171(8):4028-39
references.pmid: 14530323
references.citation: Mol Cell Biol. 1998 Nov;18(11):6538-47
references.pmid: 9774669
references.citation: Clin Chem Lab Med. 1999 Mar;37(3):199-204
references.pmid: 10353461
references.citation: Eur J Immunol. 2003 Jun;33(6):1633-41
references.pmid: 12778481
references.citation: Eur J Immunol. 2004 Jan;34(1):251-62
references.pmid: 14971051
references.citation: Science. 2004 Sep 10;305(5690):1545-7
references.pmid: 15361591
references.citation: Virus Genes. 2004 Apr;28(3):319-31
references.pmid: 15266113
references.citation: J Immunol. 2004 Jul 15;173(2):1179-83
references.pmid: 15240708
references.citation: J Virol. 2002 Sep;76(18):9011-23
references.pmid: 12186885
references.citation: J Immunol. 2004 Aug 1;173(3):1647-57
references.pmid: 15265893
references.citation: Annu Rev Immunol. 1989;7:145-73
references.pmid: 2523712
references.citation: Semin Immunol. 2004 Feb;16(1):3-9
references.pmid: 14751757
references.citation: J Virol. 2003 Oct;77(19):10658-62
references.pmid: 12970451
references.citation: J Gen Virol. 2004 Jun;85(Pt 6):1533-1543
references.pmid: 15166437
references.citation: Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42
references.pmid: 11470918
references.citation: Vaccine. 2001 Apr 6;19(20-22):2862-77
references.pmid: 11282197
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3972-7
references.pmid: 8633000
references.citation: J Immunol. 2003 Apr 1;170(7):3898-905
references.pmid: 12646659
references.citation: Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1137-46
references.pmid: 12857672
references.citation: J Biol Chem. 2004 May 21;279(21):21897-902
references.pmid: 15016800
references.citation: AIDS Patient Care STDS. 2003 Feb;17(2):47-51
references.pmid: 12650142
references.citation: Immunol Rev. 2001 Feb;179:102-18
references.pmid: 11292014
references.citation: J Immunol. 2001 Feb 15;166(4):2372-7
references.pmid: 11160295
references.citation: J Virol. 2002 Nov;76(22):11397-404
references.pmid: 12388700
references.citation: J Exp Med. 1997 Nov 17;186(10):1623-31
references.pmid: 9362523
references.citation: BMC Immunol. 2003 Jul 30;4:8
references.pmid: 12887736
references.citation: J Allergy Clin Immunol. 2001 Sep;108(3):417-23
references.pmid: 11544462
references.citation: Trends Immunol. 2004 Jul;25(7):381-6
references.pmid: 15207506